Novo Nordisk’s semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting.

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the ...

Biocon's share price saw an uptick following key regulatory approvals in India for its Liraglutide drug, which is used in the ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Starjemza, ...

Biocon said that it has received an approval from the Drugs Controller General of India (DCGI), under the central drugs standard control organisation (CDSCO), for its Liraglutide drug substance.

The HHS said it has taken the first step toward implementing most-favored-nation pricing for prescription drugs.

Prescription drugs prices have rapidly increased, but opting for generic medications and incorporating lifestyle changes are some ways to cut costs.

The Pharma world is seeing a big opportunity in GLP-1s – the new innovative fast emerging drugs for diabetes & obesity. Kiran ...

Regeneron (REGN) performed poorly. REGN stock entered a prolonged downtrend, despite no major news that would explain the decline. Last Friday, May 30, Regeneron and its drug development partner ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...